Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Posts Rise in Q2 Revenues; Initiates Stock Buyback Plan

NEW YORK, July 27 (GenomeWeb News) - Third Wave Technologies today reported an increase in its second-quarter revenues, accompanied by narrowed losses and a rise in R&D spending. Additionally, the company announced that its board of directors has approved a stock repurchase plan for up to 5 percent of the company's 40.4 million outstanding shares.

 

At the stock's current value, the buyback plan could be worth as much as $6.7 million.

 

Third Wave reported total revenues of $12.6 million for the quarter ended June 30, 2004 -- a 40 percent increase over total revenues of $8.8 million for the same period of 2003. The company also recorded deferred revenue of $5.1 million related to a product shipment that is "subject to acceptance" by a "key" customer.

 

The company posted a net loss of $106,000, or $.00 per diluted share, for the second quarter, compared to a net loss of $2.2 million, or $.05 per diluted share, for the year-ago period.

 

Third Wave spent $3.4 million on R&D during the quarter, up from $2.9 million in R&D spending for the second quarter of 2003.

 

The company's cash, cash equivalents, and short-term investments totaled $69.0 million as of June 30, an increase of $9.1 million from the prior quarter. The increase in cash includes the deferred payment of $5.1 million, Third Wave said.

 

Third Wave raised its product revenue guidance for 2004 from $39 million to $42 million.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.